Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAIT ASHINA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1194042895
CMS profile
235508
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$17,613.42

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,312.50 5
Honoraria $4,000.00 1
Travel and Lodging $3,511.54 16
Food and Beverage $1,789.38 31

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Lundbeck LLC $5,144.28 9
Eli Lilly and Company $4,357.88 6
Lilly USA, LLC $4,069.52 20
ABBVIE INC. $3,564.42 11
IMPEL PHARMACEUTICALS INC. $220.68 2
Biohaven Pharmaceutical Holding Company Ltd. $216.61 4
Amgen Inc. $40.03 1

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAIT ASHINA

NPI 1194042895 · CMS profile ID 235508

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194042895?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAIT ASHINA, NPI 1194042895, CMS profile ID 235508. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194042895?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SAIT ASHINA, NPI 1194042895, CMS profile ID 235508. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194042895?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SAIT ASHINA, NPI 1194042895, CMS profile ID 235508, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1194042895?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $17,613.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $136.3604/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918340031 CMS
Eli Lilly and Company $621.4004/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918362347 CMS
Biohaven Pharmaceutical Holding Company Ltd. $128.5404/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923529413 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $54,922.94 78
PY2020 $23,262.17 23
PY2021 $18,368.68 28
PY2022 $17,613.42 53
PY2023 $70,403.82 76
PY2024 $44,092.55 44
PY2025 $43,079.16 36

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $24,927.67 27
PY2024 Principal investigator $24,862.46 13
PY2023 Principal investigator $36,264.73 8
PY2022 Principal investigator $97,465.21 10
PY2021 Principal investigator $365,282.20 6
PY2020 Principal investigator $19,100.00 2
PY2019 Principal investigator $397.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,854.00 12/31/2025 Covered Recipient Teaching Hospital
BETH ISRAEL DEACONESS MEDICAL CENTER
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202406362
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Covered Recipient Teaching Hospital
BETH ISRAEL DEACONESS MEDICAL CENTER
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine No dispute reported 06/30/2026 1202406364
Principal investigator 1 Ipsen Innovation $150.00 12/12/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287312
Principal investigator 1 Ipsen Innovation $150.00 11/21/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287310
Principal investigator 1 Ipsen Innovation $150.00 11/07/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287304
Principal investigator 1 Ipsen Innovation $90.00 11/07/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287306
Principal investigator 1 Ipsen Innovation $90.00 11/07/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287308
Principal investigator 1 Ipsen Innovation $71.55 10/27/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290040
Principal investigator 1 Ipsen Innovation $71.55 10/27/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290042
Principal investigator 1 Ipsen Innovation $71.55 10/27/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290044
Principal investigator 1 Ipsen Innovation $300.00 10/10/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287298
Principal investigator 1 Ipsen Innovation $180.00 10/10/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287300
Principal investigator 1 Ipsen Innovation $300.00 10/10/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287302
Principal investigator 1 Ipsen Innovation $150.00 08/05/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287296
Principal investigator 1 Ipsen Innovation $150.00 07/15/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287290
Principal investigator 1 Ipsen Innovation $300.00 07/15/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287292
Principal investigator 1 Ipsen Innovation $90.00 07/15/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287294
Principal investigator 1 Ipsen Innovation $71.55 06/30/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290038
Principal investigator 1 Ipsen Innovation $180.00 06/18/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287284
Principal investigator 1 Ipsen Innovation $300.00 06/18/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287286
Principal investigator 1 Ipsen Innovation $300.00 06/18/2025 Non-covered Recipient Entity
Beth Israel Deaconess Medical Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287288
Principal investigator 1 ABBVIE INC. $1,435.00 05/06/2025 Covered Recipient Teaching Hospital
BETH ISRAEL DEACONESS MEDICAL CENTER
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202406275
Principal investigator 1 ABBVIE INC. $2,148.47 05/06/2025 Covered Recipient Teaching Hospital
BETH ISRAEL DEACONESS MEDICAL CENTER
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202406278
Principal investigator 1 ABBVIE INC. $9,825.00 04/25/2025 Covered Recipient Teaching Hospital
BETH ISRAEL DEACONESS MEDICAL CENTER
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202406255
Principal investigator 1 ABBVIE INC. $1,764.00 04/03/2025 Covered Recipient Teaching Hospital
BETH ISRAEL DEACONESS MEDICAL CENTER
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202406245
Principal investigator 1 ABBVIE INC. $2,500.00 01/02/2025 Covered Recipient Teaching Hospital
BETH ISRAEL DEACONESS MEDICAL CENTER
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202406172
Principal investigator 1 ABBVIE INC. $1,635.00 01/02/2025 Covered Recipient Teaching Hospital
BETH ISRAEL DEACONESS MEDICAL CENTER
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202406175